Individual research recommendation details

Recommendation ID

NG191/16

Question

What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

Any explanatory notes
(if applicable)

Suggested PICO (Population, Intervention, Comparator, Outcomes)

P: people with COVID-19 who do not need supplemental oxygen and are within 7 days of symptom onset

Subgroups of particular interest
• people with at least 1 risk factor for progression to severe COVID-19 disease, including (but not limited to):
• aged 60 or over
• immunosuppression
• obesity
• hypertension
• chronic lung disease
• cardiovascular disease
• cerebrovascular disease
• active cancer
• ethnic minorities
• pregnant women
• children and young people aged under 18
• people who have had different types of vaccines and/or different numbers of vaccine doses
• people who are at high risk of not mounting an antibody response when vaccinated against COVID-19#

I:
• antiviral-antiviral
• antiviral-monoclonal antibodies

C:
• standard care without the combination treatment

O:
• effectiveness outcomes
• COVID-19 related hospitalisation
• duration of COVID-19 related hospitalisation
• all-cause hospitalisation
• all-cause mortality
• need for mechanical ventilation
• need for non-invasive respiratory support
• ICU admission
• symptom alleviation
• adherence to therapy
• safety outcomes
• any adverse event
• adverse event leading to trial discontinuation

Source guidance details

Comes from guidance

COVID-19 rapid guideline: managing COVID-19

Number

NG191

Date issued

March 2021

Other details